India Drug Makers Amass Scientific Data To Challenge Diabetes Drug Ban
This article was originally published in PharmAsia News
Executive Summary
Lupin and Sun Pharmaceutical are among India drug makers assembling scientific data to get the Drugs Controller General of India to reverse its recent ban on pioglitazone, a common diabetes treatment.